other way to distinguish benign from malignant stem cells is genetic-based analysis to detect cancer-associated changes. Previous research found no oncologic abnormalities in stem and progenitor cells in benign breast tissue; however, oncogenes in the PI3K/Akt signaling pathway were identified in stem and progenitor cell populations in breast cancer. 9 The PI3K/Akt pathway is implicated in cell proliferation, signaling, and metastatic potential and is a target for chemotherapeutic agents now in clinical trials. [10] [11] [12] PI3K is a transmembrane protein that when activated by cellular growth signaling molecules results in initiation of cellular proliferation through phosphatidylinositol 3,4,5-trisphosphate and Akt 13, 14 ( Figure 1 ). Mutations in proteins along the PI3K/Akt signaling pathway have been found in colon, pancreatic, and lung cancer, and it is the most commonly mutated pathway in breast cancer. 10, 15, 16 The PIK3CA gene encodes the catalytic subunit of the PI3K enzyme. Activating mutations result in increased initiation of the downstream cascade. [17] [18] [19] Previous findings indicate that PIK3CA mutations are present in 30% to 40% of breast tumors. 15 Mutations have been associated with AKT1
(OMIM 164730) (4%-8% of tumors) and less frequently with HRAS (OMIM 190020) and PTEN (OMIM 601728). 10, 20, 21 Mutations of PIK3CA (OMIM 171834) cluster in "hot spots," with the 3 most common mutations at E5542K, E545K, and H1047R, although additional oncogenic mutations have been identified. 10, 17 Mutations in the pathway have been found in BCSCs, but the clinical implications have not been explored. 9 We propose that differences in tumor behavior and clinical outcomes may be due to the genetic differences in BCSCs that are present in breast cancers. 22, 23 We hypothesized that breast cancers with stem and progenitor cell mutations in genes of the PI3K/Akt signaling pathway would be associated with more aggressive breast cancers. To test this hypothesis, we correlated the mutation status of genes in the PI3K/Akt signaling pathway in malignant BCSCs with tumor pathologic features and early clinical outcomes among patients with breast cancer.
Methods
This study was approved by the Oregon Health & Science University institutional review board. Women with invasive ductal carcinoma of the breast exceeding 1.0 cm were identified at tumor board meetings and enrolled in the study. Solidtissue breast specimens were collected at the time of mastectomy or lumpectomy before any adjuvant treatment. Specimens were obtained directly from the operating room and evaluated by a pathologist, and approximately 1 g of tumor tissue was immediately transferred to the laboratory for processing in mammary epithelial cell-specific medium (Epicult; StemCell Technologies). Samples were minced and placed in a solution containing 50% mammary epithelial cell-specific medium, 50% fetal bovine serum, and 6% dimethyl sulfoxide (ATCC) and cryopreserved at −80°C for a variable period ranging from several weeks to months. Samples were thawed, the cryopreserving fluid was removed by centrifuge, and minced tissue was digested in mammary epithelial cell-specific medium containing collagenase and hyaluronidase overnight. Cells were tested for viability with trypan blue, counted, and were labeled with fluorochrome-conjugated monoclonal antibodies against human CD45 and CD31 (fluorescein isothiocyanate conjugated), CD24 (phycoerythrin), CD49f (phycoerythrin-cyanine 5, and CD44 (phycoerythrin-cyanine 7 
Results
Thirty invasive ductal breast carcinomas were obtained. The characteristics of breast tumors, including patient age at diagnosis, tumor size, and tumor hormone receptor status, are summarized in Table 1 . The mean follow-up time was 22 months after diagnosis. One patient was lost to follow-up contact. The most common tumor histologic grade was 2. Six patients (20%) had positive lymph nodes, and an additional 6 patients had micrometastatic deposits (<0.2-cm metastatic focus of tumor) identified in lymph nodes. The correlation between tumor size and macroscopic lymph node metastases did not achieve statistical significance (P > .05). All patients with macroscopic lymph node metastases underwent completion axillary lymph node dissection. Patients with only micrometastatic disease did not.
Among 30 tumors, 10 tumors (33%) had BCSCs with AKT1, HRAS, or PIK3CA mutations, 8 of which have been previously reported. 9 Three different mutations (E545K, N345K, and H1047R) were detected in PIK3CA, a single mutation was detected in AKT1, and a single mutation was detected in HRAS (Table 1) . PIK3CA G1049R (rs1219132) is considered a normal variant and was found in the lineage-negative Breast cancer stem and progenitor cells with and without mutations were assessed for CD44 positivity, and no significant difference was observed between the 2 groups. When the presence of any BCSC mutation correlated with patient and breast cancer characteristics, no statistically significant correlations were found with patient age at diagnosis, tumor size, tumor histologic grade, estrogen receptor expression, progesterone receptor expression, or ERBB2 status ( Table 2) . However, a statistically significant correlation was observed between the presence of BCSC mutations and axil- lary lymph node metastases (P = .02). This significance was more pronounced when micrometastatic disease was included (P = .001) (Figure 2) . Three of 10 patients with BCSC mutations experienced disease progression after diagnosis following indicated chemotherapy, hormone therapy, and a trastuzumab regimen. Two patients died of disease, and 1 patient has brain metastases. No patients with BCSCs without mutations have evidence of disease. At the time of writing, patients with BCSC mutations had been followed up for a mean of 29 months, while patients without BCSC mutations had been followed up for a mean of 19 months. The difference in the mean follow-up periods was statistically significant (P = .001).
Discussion
Patients with tumors in which BCSCs have a genetic abnormality of the PI3K/Akt signaling pathway are significantly more likely to have lymph node metastases. While axillary lymph node metastases are known to correlate with tumor size, BCSC mutation in this study was an independent predictor of lymph node metastasis. Because 4 of 20 patients (20%) without BCSC mutations had axillary lymph node metastases, a PI3K/Akt mutation in BCSCs may not be a requirement for axillary lymph node metastases. However, a significant correlation was found between the 2 factors, with 9 of 10 patients (90%) with BCSC mutations having nodal metastases. Five of 10 patients (50%) with BCSC mutations had axillary lymph node macrometastatic disease, and an additional 4 of 10 patients (40%) had micrometastatic disease. Micrometastatic disease in lymph nodes is of uncertain prognostic significance. 25, 26 Given the link between PI3K and metastatic potential, it could be that micrometastases harboring PI3K/Akt mutations may carry a different risk for distant metastatic disease. Longer patient follow-up periods and a larger sample size will determine if this subset of patients demonstrates an increased risk and may benefit from specifically designed use of adjuvant chemotherapy.
In the present study, we showed that tumors in which BCSCs have PI3K/Akt mutations exhibit variable hormone receptor expression, tumor histologic grade, and other tumor characteristics, suggesting that these early BCSC mutations do not restrict the type of breast cancer that develops. This finding has also been observed in murine investigations in which PIK3CA mutations in luminal cells produced heterogeneous tumors. 27 In additional support of this theory, similar PIK3CA
and AKT1 mutations are found in ductal carcinoma in situ. 20, 21 Their detection in both ductal carcinoma in situ and BCSCs suggests that they are present in the early development of breast cancer and in some cases may be responsible for promoting early breast cancer development. 21, [28] [29] [30] The retention of BCSCs along with PI3K/Akt mutations in tumors years after tumor initiation indicates that these cells continue to have an important role in tumor architecture and function. With regard to ERBB2, evidence suggests that PIK3CA mutations contribute to resistance to trastuzumab in ERBB2-positive breast cancers.
31
In this study, an insufficient number of ERBB2-amplified tumors were examined to discern if there is a correlation between BCSC abnormalities and axillary lymph nodal metastases in this specific group of tumors. PI3K/Akt signaling abnormalities also did not correlate with patient age at diagnosis. Unlike BRCA1 and BRCA2 mutations, which are associated with early-onset breast cancer, PI3K/ Akt abnormalities are not germline mutations but rather somatic mutations. Accordingly, it is not unexpected that they have a later onset than the breast cancers associated with BRCA mutations. The prognostic significance of specific PI3K/Akt signaling pathway mutations in breast c ancers remains controversial. [32] [33] [34] It is likely that the variability of these mutations, the heterogeneity of the tumors, and the complexity of the pathway contribute to this conflicting evidence. Our findings in BCSCs are consistent with studies 10, 15, [31] [32] [33] [34] showing that PIK3CA and AKT mutations in breast cancers are associated with factors that may indicate poor prognosis and decreased survival rates. However, other studies 32,35,36 have shown improved disease-free survival rates, lower tumor histologic grades, and increased rates of estrogen receptor positivity in patients with tumors bearing PIK3CA mutations. Our study findings indicate that the answer to this controversy may lie in identifying mutations in BCSCs, as well as mutations in the tumor as a whole. The collection of BCSCs from fresh surgical specimens, performance of molecular analyses, and subsequent correlation with clinical outcomes support embarking on a new way of approaching breast cancer diagnosis and treatment planning. The results of this study support concomitant evaluation of BCSCs along with assessment of the breast cancer overall. The analysis of BCSCs can generate specific information about tumor growth and metastatic potential that may not be obtained from analysis of the tumor progeny cells alone. Simultaneous molecular analyses of both the tumor and BCSCs may better identify patients who are likely to benefit from specific therapeutic regimens. Similarly, simultaneous BCSC and tumor analysis may increase the number of patients who might benefit from treatment but be missed by tumor analysis alone. For example, PI3K/Akt signaling pathway inhibitors now being tested in clinical trials may prove beneficial to patients with BCSC mutations even if genetic analysis of the accompanying tumors demonstrates no PIK/Akt mutation. The use of BCSC-specific and tumor-targeted chemotherapeutic agents may prove to be synergistic with each other, providing a novel therapeutic approach. Cancer stem cell therapeutics is an area of rapidly expanding knowledge. Future studies with larger cohorts, more outcomes data, and longer follow-up periods will allow us to more critically evaluate the significant early results reported in this study.
26. Kapoor NS, Shamonki J, Sim MS, Chung CT, Giuliano AE. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer [published online March 7, 2013 In their present investigation, Donovan et al 1 propose that differences in malignant behavior, and ultimately patient clinical outcomes, may be due to mutations identified in breast cancer stem cells, specifically alterations in the PIK3CA/AKT1 pathway. Among 30 analyzed tumors, 11 contained mutations in PIK3CA, HRAS, or AKT1. Clinical correlation revealed that individuals whose tumors contained stem cell mutations had significantly higher rates of axillary metastases (90%) and were the only patients to have disease progression. Based on these results, the authors postulated that testing for such genetic mutations among patients with breast cancer will likely have a role in the future and may be useful in therapeutic decision making and treatments.
This is an elegant study contributing to the growing evidence that implicates breast cancer stem cells in the complex clinical behavior of breast cancer. That said, some questions still need to be answered before widespread application of this testing into clinical practice. First, it will be important to see if these preliminary findings hold when more than 30 tumors are tested because this is admittedly a small sample size. Second, identifying whether these findings are consistent among all tumor types, and not just invasive ductal carcinomas, will be of interest as well. Third, revisiting the cohort to examine if follow-up times longer than 2 years result in equalization of the outcome curves is encouraged, as is a determination of how easily such testing can be adopted by pathology departments of variable size and means.
Most critically, in an era when medical fiscal responsibility is necessary and costs are much more visible, it will be mandatory to determine if such testing is economically feasible. It is not uncommon for a patient with newly diagnosed breast cancer to undergo advanced testing with magnetic resonance imaging, as well as tumor profiling with gene assays, which can individually cost multiple thousands of dollars. If breast cancer stem cell testing can be performed in a costeffective manner, and if the results ultimately yield information that influences therapeutic interventions as suggested by the authors, then additional costs will be justified, and such testing can avoid becoming just another shiny new toy.
